KRAS and colorectal carcinoma: For example, it was described that KRAS mutation is associated with suppressed Th1/cytotoxic immunity in CRC [45], whereas another work demonstrated that pathway mutations such as those in the RAS/RAF or PI3KCA pathways are associated with different expression of tumor leucocyte fraction [46].